Rabacfosadine is a novel acyclic nucleotide analogue that was designed to target and attack cancerous lymphoma cells. It has demonstrated anti-cancer activity in dogs with lymphoma, and is currently being evaluated in a pilot safety study in cats with lymphoma. Keep Reading